Abstract:Purpose: Antiangiogenic therapy is commonly being used for the treatment of glioblastoma. However, the benefits of angiogenesis inhibitors are typically transient and resistance often develops. Determining the mechanism of treatment failure of the VEGF monoclonal antibody bevacizumab for malignant glioma would provide insight into approaches to overcome therapeutic resistance. Experimental design: In this study, we evaluated the effects of bevacizumab on the autophagy of glioma cells and determined target genes involving in the regulation of bevacizumab-induced autophagy. Results: We demonstrated that bevacizumab treatment increased expression of autophagy markers and autophagosome formation in cell culture experiments as well as in in vivo studies. Gene expression profile analysis performed on murine xenograft models of glioblastoma showed increased transcriptional levels of STAT1/IRF1 signaling in bevacizumab resistant tumors compared to control tumors. In vitro experiments showed that bevacizumab treatment increased IRF1 expression in a dose and time dependent manner, which was coincident with bevacizumab-mediated autophagy. Down regulation of IRF1 by shRNA blocked autophagy and increased AIF-dependent apoptosis in bevacizumab-treated glioma cells. Consistently, IRF1 depletion increased the efficacy of anti-VEGF therapy in a glioma xenograft model, which was due to less bevacizumab-promoted autophagy and increased apoptosis in tumors with down-regulated IRF1. Conclusions: These data suggest that IRF1 may regulate bevacizumab-induced autophagy, and may be one important mediator of glioblastoma resistant to bevacizumab.

Supplementary Figure 4 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 2 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 6 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 5 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 3 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Table 2 from Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure 1 from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Table 1 from Interferon Regulatory Factor-1 Signaling Regulates the Switch between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Supplementary Figure Legends from Interferon Regulatory Factor-1 Signaling Regulates the Switch Between Autophagy and Apoptosis to Determine Breast Cancer Cell Fate

Ifr-9/Stat2 Functional Interaction Drives Retinoic Acid-Induced Gene G Expression Independently Of Stat1

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy

Supplementary Figure S4 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Supplementary Figure S6 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer

Elucidating the power of arginine restriction: taming type I interferon response in breast cancer via selective autophagy

Supplementary Figure 1 from KLF4-Mediated Negative Regulation of IFITM3 Expression Plays a Critical Role in Colon Cancer Pathogenesis

Supplementary Figure 1 from Absence of the Full-Length Breast Cancer–Associated Gene-1 Leads to Increased Expression of Insulin-Like Growth Factor Signaling Axis Members

Supplementary Figure S2 from HER2/EGFR–AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer